AIS/Spectranetics
This article was originally published in The Gray Sheet
Executive Summary
Excimer laser manufacturers renew vows for merger; the latest agreement calls for Advanced Interventional Systems (LAIS) shareholders to receive .80282 shares of Spectranetics stock for each LAIS share, giving them 45% ownership of the new company. The merger, subject to "customary conditions" and shareholder approval, is expected to close in four months. Following the merger, Spectranetics' President and CEO Robert DePasqua would serve as President, CEO and a director of the new firm, while LAIS director David Goldsmith would serve as chairman. AIS Chairman and CEO Robert Wall has resigned. An earlier acquisition offer by Spectranetics and merger proposal by LAIS, which were floated after an initial merger agreement fell through, were terminated in December ("The Gray Sheet" Dec. 20, In Brief)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.